PHILADELPHIA (July 11, 2018) – Fox Chase Cancer Center is pleased to announce the publication of Molecular Determinants of Head and Neck Cancer, 2nd Edition, edited by Erica Golemis, PhD, deputy chief science officer at Fox Chase Cancer Center, and Barbara Burtness, MD, Disease Aligned Research Team Leader of the Head and Neck Cancers Program at Yale Cancer Center.
This new edition informs readers of significant advances in the understanding of this disease and the new therapies that have become available, with a focus on novel drug targets to improve the outcomes of head and neck squamous cell carcinomas (HNSCC). HNSCCs arise in the oral cavity, pharynx, and larynx; approximately 600,000 new cases will be diagnosed worldwide in 2018.
The book specifically addresses the biology and treatment of different subtypes of HNSCC, including the rapidly growing class of human papillomavirus (HPV) – driven HNSCC. Along with Golemis and Burtness, several current and former Fox Chase faculty members contributed to this book, including Jeffrey Liu, Camille Ragin, Suraj Peri, Andrew J. Andrews, Ranee Mehra, and Ilya G. Serebriiskii.
“In the four years, since the original book was published, we have seen considerable advances in understanding disease mechanisms, and developing new treatments, including promising new immunotherapies,” said Golemis. “The key to success in treating HNSCC comes from our ability to translate bench research into clinical trials, which is emphasized in this updated edition.”
The second edition is available for purchase now.